GPT-Rosalind vs Claude Opus 5.5: Both Labs Put a Gate in Front of Biology

GPT-Rosalind has been available since 16 April 2026 and Claude Opus 5.5 since 22 September 2026, so neither of these is a launch story. What is new is the paperwork around them. On 15 October O​penAI published an academic plan that gives eligible labs up to 30 ChatGPT Business seats at no charge for up to twelve months and states, in the same document, that API access is not included. Six days later it published a first-party research note in which a distributed agent run proposed a cholesterol-trafficking hypothesis for a neurodegenerative condition in thirty-two minutes. The specialist is being pushed into universities while its API stays behind a review. Anthropic has the mirror arrangement: a general model you can call today, whose biology answers quietly fall back to an older model unless your account is verified. Two labs, two gates, and the only question that matters is which gate your work is standing behind. Access changes and silent model fallbacks like the ones described here are recorded with their dates and sources in the AI Incident Archive, alongside the rest of the model and vendor incidents we follow.

Two gates, two logics

Anthropic's arrangement is documented in the Claude Opus 5.5 launch material and is easy to miss because it appears as a configuration label rather than a policy: the model ships with the safeguard tier previously reserved for Claude Fable 5.1, because it is judged comparable on biology and cybersecurity. In practice most cybersecurity requests are rerouted to Claude Opus 4.8, and biology work falls back to Claude Opus 5 unless the account is verified through Anthropic's Life Sciences or Cyber Verification programmes.

That is a fallback, and it is worth being precise about what it means for a lab. You get a competent general model answering your biology question — Claude Opus 5, not the newer model — and unless you have gone through verification you may not notice the substitution at all. The capability is there; the newest version of it is held back.

O​penAI's arrangement is the mirror image. GPT-Rosalind is reachable through ChatGPT, Codex and the API, but only by organisations that clear the trusted-access programme. Since 11 September 2026 it has been open globally to eligible organisations rather than to a named partner list, and published pricing took effect on 5 October 2026. The model you get is the specialist; the open question is whether you get it.

• Gate type — GPT-Rosalind: an application and review before the first call. Claude Opus 5.5: silent model substitution on sensitive domains, removable by verification.

• What is withheld — GPT-Rosalind: the model itself. Claude Opus 5.5: the newest model's biology capability, replaced by its predecessor's.

• Time to access — GPT-Rosalind: however long review takes, with no published service level. Claude Opus 5.5: immediate for non-biology work; verification-dependent for biology.

• Failure mode if you are unverified — GPT-Rosalind: no access, and an error you can see. Claude Opus 5.5: a working answer from a different model, which you may not see.

That last line is the one that should shape procurement. A hard gate is annoying and honest. A soft gate is convenient and produces results whose provenance you have to check, especially if your pipeline logs the model you requested rather than the model that answered.

What changed in October, and why it is the real story

The 15 October academic plan is the first time O​penAI has separated access to the assistant from access to the model. The seats are ChatGPT Business, capped at 30 per institution, free for up to twelve months, and the plan requires the same trusted-access approval as any other route. Principal investigators manage permissions; institutional verification is a step in the process. Enterprise labs are told to negotiate their own agreement rather than use the academic path. And the sentence that matters most for anyone building anything: API access is not included at this time.

So a university group can now get the model in a chat window for free and still cannot call it from a pipeline. That is not a cynical reading; it is the literal text of the plan, and it produces a strange split inside a single lab. The wet-lab scientists get a browser tab. The computational group gets nothing until it clears review on its own account and starts paying $5.00 per million input tokens.

The 21 October research note shows what the paid route is for. A run of thousands of cooperating agents, built with PerturbAI and Scripps, screened more than 700 references down to 11 and produced a hypothesis about cholesterol trafficking in a neurodegenerative disease in 32 minutes; blinded reviewers preferred the machine output in roughly three quarters of comparisons, and the preprint went up under a CC-BY licence on 16 October. It is a first-party result, so treat the preference figure as a vendor claim — but it is the first public demonstration that the gated model is being used for something other than benchmark tables.

Neither October document changes the comparison on price or capability. Both change who can enter it.

The rate card stopped being a tie

Until September this comparison was unusually clean: O​penAI's specialist and Anthropic's flagship both sat at $5.00 per million input tokens and $25.00 per million output. Then Anthropic cut its flagship on 22 September 2026 — $4.00 in, $20.00 out, cache reads down from $0.50 to $0.20 — and the tie broke. GPT-Rosalind has not moved from the rates published in its September update.

• Input — GPT-Rosalind $5.00 per 1M vs Claude Opus 5.5 $4.00. The specialist costs 25% more per input token.

• Output — GPT-Rosalind $25.00 per 1M vs Claude Opus 5.5 $20.00. Also 25% more.

• Cached input — GPT-Rosalind $0.50 vs Claude Opus 5.5 $0.20. This is the line that compounds on long agent runs, and here the gap is 2.5×.

• Cache write — O​penAI's pricing page carries no cache-write line for GPT-Rosalind. Claude Opus 5.5 charges $5 per 1M for a five-minute write and $8 for an hour.

• Context and output — Both carry a 1M-token context window; Claude Opus 5.5 documents 128K max output, with 300K available on the Batch API behind a beta header.

• Modalities — Claude Opus 5.5 takes text, image and file input and returns text. GPT-Rosalind handles scientific file inputs through ChatGPT, Codex and the API; O​penAI publishes no general image-input claim for it.

The cache line deserves the emphasis it does not usually get. A discovery workflow is a long conversation with a large system prompt — the atlas schema, the tool definitions, the house protocol — re-sent on every turn. At $0.20 against $0.50 per million cached tokens, a run that leans on caching is materially cheaper on the generalist before a single biology token is generated. Whether that matters depends on whether the specialist's per-token answer quality closes the gap, and that is the next section.

What the specialist has actually measured

All of the following is O​penAI's own evaluation, published with the model's capability update, and none of it has been independently reproduced. The comparisons are against GPT-5.5, O​penAI's own general model, not against anything Anthropic makes.

• MedChemBench — 27.5% for GPT-Rosalind against 25.1% for GPT-5.5, using 7.2% fewer tokens. A benchmark O​penAI designed to cover structure-activity relationships, potency and ADME prediction, and retrosynthesis.

• GeneBench — 21.6% against 20.4%, with 31% fewer tokens, on long-horizon genomics and quantitative biology analysis.

• LabWorkBench — 63.2% against 55.8%, using 5.3% fewer tokens, on linking perturbations to outcomes in real wet-lab protocols. The data is proprietary, which is a point in favour: it cannot have leaked into training.

• BixBench — O​penAI claims the leading score among models with published results, and does not state the figure in prose. Two secondary write-ups cite 0.751 and 0.761, so treat the exact number as unsettled.

• LifeSciBench — the vendor's headline is a 4.42% increase in performance per token, on an externally expert-judged benchmark across six workflow areas.

Read the absolute numbers, not the deltas. A 27.5% score on a medicinal-chemistry benchmark is not a model that does drug discovery; it is a model that beats its predecessor on a hard test where both score low. The 4.42% headline is a ratio of accuracy to tokens, which is a legitimate efficiency measure and a strange thing to put at the top of a launch page. What these numbers do establish is that the tuning is real and specific: the gains show up on chemistry and wet-lab tasks, not on general reasoning.

There is no public biology benchmark on which GPT-Rosalind and Claude Opus 5.5 have both been scored. Anyone presenting a head-to-head number is either comparing different benchmarks or comparing a vendor run against an independent one, and both are invalid. That absence is the single most important fact in this matchup.

What the generalist has actually measured

Claude Opus 5.5 has the independent record, and it is broad. On Artificial Analysis's Intelligence Index — the v4.3.2 revision, read in late October 2026 — it scores 57.6, which puts it ahead of every other model on that board. The launch-day reading on the previous revision of the index was 54, so the number has moved with the methodology as well as the model; cite the revision when you cite the score.

Anthropic's own launch table adds the domain detail, all vendor-reported: Terminal-Bench 4.0 at 66.4%, FrontierCode v1.1 at 54.4%, CursorBench 4.0 at 57.8%, GDPval-AA v2.1 at 1846 Elo, OSWorld 2.0 at 81.8%. Anthropic also cautions, in its own material, that at this capability level benchmark margins are "a less reliable guide to real-world differences" — a sentence worth remembering the next time a leaderboard gap is quoted at you.

None of that is biology. It is the profile of a model built to be good at everything, and it is the reason the comparison is not simply "specialist beats generalist on domain tasks." A biotech's token spend is mostly not biology: it is code, data pipelines, document review, and the agent scaffolding around the science. On that majority of the workload Claude Opus 5.5 is cheaper, independently measured, and available without an application.

The one thing that decides it: does your biology work count as biology

Here is the asymmetry nobody puts in a comparison table. GPT-Rosalind's gate is about who you are. Claude Opus 5.5's gate is about what you ask. A university lab running a cholesterol-trafficking assay in neurons is exactly the use case O​penAI's trusted-access review exists for, and exactly the use case that Anthropic's safeguard tier routes away from unless the account is verified.

The practical consequence: if you clear verification on both sides, you have a real choice between a specialist at $5/$25 and a generalist at $4/$20, and the specialist's domain tuning is the reason to pay the 25% premium. If you clear neither, you have no choice at all — you get Claude Opus 5 answering biology questions and no GPT-Rosalind, and the comparison is academic.

There is a third case, and it is probably the most common one inside a company: the biology team is verified and the platform team is not. Then the two models are not alternatives, they are different tools for different queues, and the interesting engineering problem is keeping the routing honest — making sure a request that needs the specialist does not silently land on a generalist because the specialist's key was rate-limited.

Running both without pretending they are interchangeable

Claude Opus 5.5 is on OrcaRouter at the provider's list price — $4.00 input, $20.00 output, $0.20 cached input per million tokens, with 0% markup, so Anthropic's September cut reached our catalogue the day it was published. GPT-Rosalind is not on OrcaRouter; it is not on any third-party router, and access runs through O​penAI's trusted-access programme directly. We are not going to imply otherwise.

What that combination is actually good for is the split-queue pattern above. The general half of a research platform — the code that parses atlas outputs, the agent orchestration, the literature summarisation that does not need domain tuning, the report generation — runs on Claude Opus 5.5 through one key alongside 200+ other models, with automatic failover so a provider hiccup moves the request instead of failing the run. The biology half stays on the direct Rosalind key. The routing DSL is what lets you express that as a rule rather than a convention: a named route for the specialist, a fallback for everything else, and no silent substitution in either direction.

That last part is the design principle this whole matchup argues for. Anthropic's soft gate exists because silent substitution is convenient. If you are building a regulated pipeline, you want the substitution to be a decision you configured, logged, and can defend — not something the vendor did on your behalf.

What would change this comparison

Three things, in order of likelihood. O​penAI could extend the academic plan to include API access, which would put free specialist capacity inside every eligible university and make the generalist the paid option. Anthropic could extend verification faster than O​penAI extends trusted access, which would make the generalist the pragmatic route to frontier biology capability for a mid-sized lab. O​penAI could cut GPT-Rosalind's price to meet the new flagship tier, which would collapse the 25% premium and make the domain tuning close to free. Or an independent evaluator could publish a biology benchmark that both models sit, which would replace this entire argument with a number.

Until one of those happens, the decision rule is narrow and unglamorous. If your work is molecular biology and you can pass a review, GPT-Rosalind is the only frontier model tuned for it, and 25% is not a large premium for a domain specialist. If your work is anything else, or your biology work is incidental, Claude Opus 5.5 is cheaper, independently scored, and ungated — and the safeguard fallback is a feature to understand rather than a reason to avoid it, as long as you know when it fires.